Company: XXII
Filing Date: 2025-08-26
Form Type: 424B5
Source: 0001641172-25-025541
Chunk: 29

Company: 22nd Century Group, Inc.
Filing Date: 2025-08-26
Form: 424B5
Chunk 29
---
                                                                                                                                
 competitors generally have, and any future competitors may have, greater financial resources and name recognition than we do, and  
 they may therefore develop products or other technologies similar or superior to ours, or otherwise compete more successfully than 
 we do.                                                                                                                             |

| ● | Our                                                                                                                                   
 research and development process may not develop marketable products, which would result in loss of our investment into such process. |

| 1 |

| ● | Our                                                                                                                              
 ability to successfully integrate the operations of GVB Biopharma into ours and achieve the expected synergies with the acquired 
 business.                                                                                                                        |

| ● | We                                                                                                                          
 may acquire or invest in other companies, which may divert our management’s attention, result in additional dilution to our 
 stockholders, and consume resources that are necessary to sustain our business or result in losses.                         |

| ● | The                                                                                                                        
 coronavirus pandemic (COVID-19) or another pandemic may cause a variety of business disruptions and future business risks. |

| ● | The                                                                                                                                  
 failure of our information systems to function as intended or their penetration by outside parties with the intent to corrupt them   
 could result in business disruption, litigation and regulatory action, and loss of revenue, assets, or personal or confidential data 
 (cybersecurity).                                                                                                                     |

| ● | We                                                                                                                    
 may be unsuccessful at commercializing our Very Low Nicotine Content “VLNC” tobacco as a Modified Exposure Cigarette. |

| ● | The                                                                                                                                  
 manufacturing of tobacco products subjects us to significant governmental regulation and the failure to comply with such regulations 
 could have a material adverse effect on our business and subject us to substantial fines or other regulatory actions.                |

| ● | We                                                                                                                                
 may become subject to litigation related to cigarette smoking and/or exposure to environmental tobacco smoke, or ETS, which could 
 severely impair our results of operations and liquidity.                                                                          |

| ● | The                                                                                                                               
 loss of a significant customer for whom we manufacture tobacco products could have an adverse impact on our results of operation. |

| ● | Product                                                                                                     
 liability claims, product recalls, or other claims could cause us to incur losses or damage our reputation. |

| ● | The                                                               
 FDA could force the removal of our products from the U.S. market. |

| ● | Negative                                                                                                                           
 press from being in the hemp/cannabis space could have a material adverse effect on our business, financial condition, and results 
 of operations.                                                                                                                     |

| ● | Any                                                                                                    
 business-related